Kancera
1,722 SEK -0,35%Vær den første som følger denne virksomhed
Kancera is a pharmaceutical company. The company develops pharmaceuticals that counteract injuries in acute and chronic inflammation. The products are developed primarily to counteract hyper-inflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe virus infections. Kancera is planning two Phase II clinical trials, in covid-19 and in cardiac patients. Kancera conducts research and development within Karolinska Institutet Science Park in Stockholm.
Læs mereOmsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
KAN
Daglig lav / høj pris
1,652 / 1,728
SEK
Markedsværdi
208,68 mio. SEK
Aktieomsætning
137,63 t SEK
Volumen
80 t
Seneste videoer
Finanskalender
Delårsrapport
23.08.2024
Delårsrapport
15.11.2024
Årsrapport
21.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Avanza Pension | 8,9 % | 8,9 % |
Nordnet Pensionsförsäkring | 1,5 % | 1,5 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Phase Ib completed and the recommended phase II dose is set in the ongoing KANDOVA study
Redeye: Kancera - Underestimated optionality
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools